Ankit Mangla, MD
Hematology & Oncology · Cleveland, OHNPI 1871841908
Payments from drug & device makers
Across 1,335 payments — averaging $2505.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$2.3M
- Boehringer Ingelheim$281K
- Novartis$258K
- Springworks Therapeutics, Inc.$211K
- Trillium Therapeutics USA, LLC$104K
- E.r. Squibb & Sons, L.L.C.$102K
- plus $92K from 30 others
Across 12 payments — averaging $713.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$6K
- Regeneron$2K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 1,034 | $2,297,307 |
| Boehringer Ingelheim | 8 | $281,343 |
| Novartis | 12 | $257,805 |
| Springworks Therapeutics, Inc. | 153 | $210,677 |
| Trillium Therapeutics USA, LLC | 40 | $103,722 |
| E.r. Squibb & Sons, L.L.C. | 14 | $102,002 |
| Pfizer | 3 | $37,482 |
| Amgen | 14 | $26,857 |
| Regeneron Healthcare Solutions, Inc. | 5 | $12,309 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 4 | $9,307 |
| Deciphera Pharmaceuticals Inc. | 6 | $2,847 |
| Boehringer Ingelheim International GmbH | 3 | $1,967 |
| Merck | 8 | $139 |
| Array Biopharma Inc | 2 | $109 |
| Eisai Inc. | 4 | $89 |
| Novartis Pharma AG | 1 | $77 |
| AstraZeneca | 3 | $47 |
| Bayer | 2 | $37 |
| Seagen Inc. | 2 | $30 |
| Tempus AI, Inc | 1 | $24 |
| Bristol Myers Squibb | 1 | $24 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $23 |
| Sanofi | 1 | $23 |
| Karyopharm Therapeutics Inc. | 1 | $22 |
| Puma Biotechnology, Inc. | 1 | $19 |
| Foundation Medicine, Inc. | 1 | $18 |
| Sun Pharmaceutical Industries Inc. | 1 | $17 |
| Shire North American Group Inc | 1 | $16 |
| Incyte Corporation | 1 | $16 |
| Epizyme, Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Apellis Pharmaceuticals, Inc. | 1 | $15 |
| Taiho Oncology, Inc. | 1 | $15 |
| Tolmar, Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $13 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $11 |
How this compares
$3,344,453 in reported general payments places this provider in the 95th percentile of 450 hematology & oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Cleveland
- Afshin DowlatiCleveland$25.1M
- Brian HillCleveland$11.6M
- Christopher HoimesCleveland$7.5M
- Balazs HalmosCleveland$7M
- Dale ShepardCleveland$5.1M
- Paolo CaimiCleveland$4.2M
- Allison WinterCleveland$4.2M
- Nathan PennellCleveland$3.8M
- David BajorCleveland$3.3M
- Aziz NazhaCleveland$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.